Privia Health Group (PRVA) Expected to Announce Earnings on Thursday

Key Points

• Privia Health Group is expected to report Q3 2026 results before market open on November 5. Analysts forecast earnings of $0.0906 per share and revenue of $610.72 million.
• In the prior quarter, Privia exceeded expectations with EPS of $0.19 versus $0.07 estimated and revenue of $632.63 million, up 21.4% year over year.
• Analysts maintain a generally positive outlook, with 11 Buy ratings and three Holds, an overall “Moderate Buy” consensus, and a $31 average price target versus the stock’s recent $21.84 price.

Privia Health Group (NASDAQ:PRVA - Get Free Report) is projected to post its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Privia Health Group to post earnings of $0.0906 per share and revenue of $610.72 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.07 by $0.12. The firm had revenue of $632.63 million for the quarter, compared to the consensus estimate of $597.33 million. Privia Health Group had a return on equity of 3.52% and a net margin of 1.19%. The firm's quarterly revenue was up 21.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.24 EPS. On average, analysts expect Privia Health Group to post $0.27 EPS for the current fiscal year and $0.41 EPS for the next fiscal year.

Privia Health Group Trading Up 0.0%

NASDAQ:PRVA opened at $21.84 on Thursday. The firm has a market cap of $2.79 billion, a P/E ratio of 104.00 and a beta of 0.80. The stock's 50 day simple moving average is $20.86 and its 200-day simple moving average is $22.67. Privia Health Group has a 12-month low of $18.92 and a 12-month high of $28.82.

Analyst Ratings Changes

A number of brokerages have recently issued reports on PRVA. Weiss Ratings reiterated a "hold (c)" rating on shares of Privia Health Group in a report on Tuesday, September 29th. Zacks Research upgraded shares of Privia Health Group from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 5th. Citigroup reissued a "buy" rating on shares of Privia Health Group in a report on Thursday, July 23rd. Finally, Canaccord Genuity Group set a $32.00 target price on shares of Privia Health Group in a research report on Friday, August 7th. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $31.00.

Privia Health Group Company Profile

Privia Health Group, Inc is a physician-enablement company that partners with independent medical practices to support the delivery of coordinated, value-based care. The company provides an integrated platform designed to help physicians manage clinical, administrative and financial functions while maintaining ownership and control of their practices.

Its services include practice management, electronic health record and technology support, revenue-cycle management, payer contracting, population-health analytics, care-management programs and administrative assistance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.